{"denomUnitsSelected":"Participants","description":"Time from initiation of daratumumab-based combination regimen to disease progression, where disease progression is according to the IMWG criteria, death, or last disease evaluation before the start of any subsequent anti-myeloma therapy (whichever occurs first).","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years after start of study treatment","title":"Progression-free Survival (PFS)","type":"SECONDARY"}